Biogen

Biogen BIIB Stock

$253.40   1.165761%
Add to favorites
Market Cap
$37.46B
LOW - HIGH [24H]
$249.52 - $255.04
VOLUME [24H]
$1.03M
P/E Ratio
108.29
Earnings per share
$2.34
ISIN
US09062X1037
Price   Prediction

Biogen Price Chart

Sorry, that's all we've gotfor now...

Biogen (BIIB) stock price today is 253.4 USD on Tech Market Large (+1.17% on the day). Updated .

Biogen BIIB Financial and Trading Overview

Biogen stock price 253.4 USD
Previous Close 250.48 USD
Open 250.58 USD
Bid 253.33 USD x 100
Ask 263.99 USD x 100
Day's Range 249.52 - 255.04 USD
52 Week Range 160.36 - 261 USD
Volume 1.03M USD
Avg. Volume 1.08M USD
Market Cap 37.46B USD
Beta (5Y Monthly) 0.086
PE Ratio (TTM) 108.290596
EPS (TTM) 2.34 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 268.26 USD

BIIB Valuation Measures

Enterprise Value 43.96B USD
Trailing P/E 108.290596
Forward P/E 15.585511
PEG Ratio (5 yr expected) 3.45
Price/Sales (ttm) 3.637618
Price/Book (mrq) 1.979301
Enterprise Value/Revenue 4.269
Enterprise Value/EBITDA 13.311

Trading Information

Biogen Stock Price History

Beta (5Y Monthly) 0.086
52-Week Change 53.87%
S&P500 52-Week Change 13.32%
52 Week High 261 USD
52 Week Low 160.36 USD
50-Day Moving Average 233.35 USD
200-Day Moving Average 205.15 USD

BIIB Share Statistics

Avg. Volume (3 month) 1.08M USD
Avg. Daily Volume (10-Days) 1.06M USD
Shares Outstanding 147.82M
Float 147.29M
Short Ratio 4.05
% Held by Insiders 0.70%
% Held by Institutions 98.69%
Shares Short 5.45M
Short % of Float 4.11%
Short % of Shares Outstanding 3.69%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 3:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 3.37%
Operating Margin (ttm) 23.50%
Gross Margin 75.76%
EBITDA Margin 32.06%

Management Effectiveness

Return on Assets (ttm) 4.93%
Return on Equity (ttm) 1.87%

Income Statement

Revenue (ttm) 10.3B USD
Revenue Per Share (ttm) 69.9 USD
Quarterly Revenue Growth (yoy) 10.59%
Gross Profit (ttm) 7.8B USD
EBITDA 3.3B USD
Net Income Avi to Common (ttm) 347.5M USD
Diluted EPS (ttm) 2.34
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 1.3B USD
Total Cash Per Share (mrq) 8.82 USD
Total Debt (mrq) 7.8B USD
Total Debt/Equity (mrq) 41.23 USD
Current Ratio (mrq) 1.946
Book Value Per Share (mrq) 128.025

Cash Flow Statement

Operating Cash Flow (ttm) 2.25B USD
Levered Free Cash Flow (ttm) 808.12M USD

Profile of Biogen

Country United States
State MA
City Cambridge
Address 225 Binney Street
ZIP 02142
Phone 617 679 2000
Website https://www.biogen.com
Industry Drug Manufacturers - General
Sector(s) Healthcare
Full Time Employees 7500

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Q&A For Biogen Stock

What is a current BIIB stock price?

Biogen BIIB stock price today per share is 253.4 USD.

How to purchase Biogen stock?

You can buy BIIB shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Biogen?

The stock symbol or ticker of Biogen is BIIB.

Which industry does the Biogen company belong to?

The Biogen industry is Drug Manufacturers - General.

How many shares does Biogen have in circulation?

The max supply of Biogen shares is 147.82M.

What is Biogen Price to Earnings Ratio (PE Ratio)?

Biogen PE Ratio is 108.29059600 now.

What was Biogen earnings per share over the trailing 12 months (TTM)?

Biogen EPS is 2.34 USD over the trailing 12 months.

Which sector does the Biogen company belong to?

The Biogen sector is Healthcare.

Biogen BIIB included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 25136.27 USD —
-0.91
7.74B USD — 24872.41 USD — 25423.09 USD — — 7.74B USD —
us S&P 500 INDEX SPX US 7561.67 USD —
-0.4
2.75B USD — — — — — — 2.75B USD —
us S&P 500 (Yahoo.com) GSPC US 7561.67 USD —
-0.4
2.73B USD — 7499.4 USD — 7621.78 USD — — 2.73B USD —
us US100 NDX US 27943.74 USD —
-1.22
1.52B USD — 27609.71 USD — 28295.8 USD — — 1.52B USD —
us S&P 100 SP100 US 3720.62 USD —
-0.5
1.43B USD — 3689.79 USD — 3753.79 USD — — 1.43B USD —
us Dow Jones U.S. Biotechnology In DJUSBT US 3996.56 USD —
-0.14
87.81M USD — 3971.64 USD — 4009.69 USD — — 87.81M USD —
us US Tech-100 Ex-Tech Sector NDXX US 6133.95 USD —
+0.19
— — 6104.58 USD — 6148.51 USD — — — —
us US Tech-100 ESG Net Notional Tot NDXESG24 US 2297.07 EUR 2651.59 USD
-1.05
— — 2266.83 EUR 2616.68 USD 2324.63 EUR 2683.4 USD — — —
us US Tech-100 Micro Index XND US 279.44 USD —
-1.22
— — 276.1 USD — 282.96 USD — — — —
us US Tech-100 Equal Weighted NDXE US 9791.58 USD —
-0.64
— — 9688.74 USD — 9857.64 USD — — — —
us US Tech Composite Total Return XCMP US 31061.46 USD —
-0.9
— — 30735.41 USD — 31415.87 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech-100 After Hours Indicato QIV US 27731.11 USD —
-1.97
— — 27724.65 USD — 27901.77 USD — — — —
us US Tech-100 Reduced Value Index NQX US 5588.75 USD —
-1.22
— — 5521.94 USD — 5659.18 USD — — — —
us US Tech-100 PM Settlement Value XQC US 16331.98 USD —
+1.13
— — 16331.98 USD — 16331.98 USD — — — —
us US Tech Global Select Market Com NQGS US 12378.66 USD —
-0.9
— — 12248.6 USD — 12520.36 USD — — — —
us US Tech-100 Notional Net Total R XNDXNNR US 32590.27 USD —
-1.22
— — 32200.72 USD — 33000.86 USD — — — —
us US Tech CRD Global Sustainabilit NQCRD US 1735.62 USD —
0
— — 1715.94 USD — 1757.95 USD — — — —
us US Tech-100 Target 25 Index NDXT25 US 2001.62 USD —
<0.01
— — 1985.64 USD — 2007.47 USD — — — —
us US Tech-100 Total Return XNDX US 34167.38 USD —
-1.22
— — 33758.98 USD — 34597.83 USD — — — —
$2.2T
Total marketcap
$70.82B
Total volume
BTC 59.35%   •   ETH 10.12%
Dominance
Select currency